Ingrid A Binswanger1,2,3,4, Deborah Rinehart5,6, Shane R Mueller7, Komal J Narwaney7, Melanie Stowell6, Nicole Wagner7,5, Stan Xu8, Rebecca Hanratty5,9, Josh Blum5,9, Kevin McVaney9, Jason M Glanz7,10. 1. Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA. ingrid.a.binswanger@kp.org. 2. Colorado Permanente Medical Group, Aurora, CO, USA. ingrid.a.binswanger@kp.org. 3. Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA. ingrid.a.binswanger@kp.org. 4. Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA. ingrid.a.binswanger@kp.org. 5. Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA. 6. Denver Health, Center for Health Systems Research, Office of Research, Denver Health and Hospital Authority, Denver, CO, USA. 7. Institute for Health Research, Kaiser Permanente Colorado, Aurora, CO, USA. 8. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA. 9. Department of Medicine, Denver Health, Denver, CO, USA. 10. Colorado School of Public Health, Aurora, CO, USA.
Abstract
BACKGROUND: Although naloxone prevents opioid overdose deaths, few patients prescribed opioids receive naloxone, limiting its effectiveness in real-world settings. Barriers to naloxone prescribing include concerns that naloxone could increase risk behavior and limited time to provide necessary patient education. OBJECTIVE: To determine whether pharmacy-based naloxone co-dispensing affected opioid risk behavior. Secondary objectives were to assess if co-dispensing increased naloxone acquisition, increased patient knowledge about naloxone administration, and affected opioid dose and other substance use. DESIGN: Cluster randomized pragmatic trial of naloxone co-dispensing. SETTING: Safety-net health system in Denver, Colorado, between 2017 and 2020. PARTICIPANTS: Seven pharmacies were randomized. Pharmacy patients (N=768) receiving opioids were followed using automated data for 10 months. Pharmacy patients were also invited to complete surveys at baseline, 4 months, and 8 months; 325 survey participants were enrolled from November 15, 2017, to January 8, 2019. INTERVENTION: Intervention pharmacies implemented workflows to co-dispense naloxone while usual care pharmacies provided usual services. MAIN MEASURES: Survey instruments assessed opioid risk behavior; hazardous drinking; tobacco, cannabis, and other drug use; and knowledge. Naloxone dispensings and opioid dose were evaluated using pharmacy data among pharmacy patients and survey participants. Intention-to-treat analyses were conducted using generalized linear mixed models accounting for clustering at the pharmacy level. KEY RESULTS: Opioid risk behavior did not differ by trial group (P=0.52; 8-month vs. baseline adjusted risk ratio [ARR] 1.07; 95% CI 0.78, 1.47). Compared with usual care pharmacies, naloxone dispensings were higher in intervention pharmacies (ARR 3.38; 95% CI 2.21, 5.15) and participant knowledge increased (P=0.02; 8-month vs. baseline adjusted mean difference 1.05; 95% CI 0.06, 2.04). There was no difference in other substance use by the trial group. CONCLUSION: Co-dispensing naloxone with opioids effectively increased naloxone receipt and knowledge but did not increase self-reported risk behavior. TRIAL REGISTRATION: Registered at ClinicalTrials.gov ; Identifier: NCT03337100.
BACKGROUND: Although naloxone prevents opioid overdose deaths, few patients prescribed opioids receive naloxone, limiting its effectiveness in real-world settings. Barriers to naloxone prescribing include concerns that naloxone could increase risk behavior and limited time to provide necessary patient education. OBJECTIVE: To determine whether pharmacy-based naloxone co-dispensing affected opioid risk behavior. Secondary objectives were to assess if co-dispensing increased naloxone acquisition, increased patient knowledge about naloxone administration, and affected opioid dose and other substance use. DESIGN: Cluster randomized pragmatic trial of naloxone co-dispensing. SETTING: Safety-net health system in Denver, Colorado, between 2017 and 2020. PARTICIPANTS: Seven pharmacies were randomized. Pharmacy patients (N=768) receiving opioids were followed using automated data for 10 months. Pharmacy patients were also invited to complete surveys at baseline, 4 months, and 8 months; 325 survey participants were enrolled from November 15, 2017, to January 8, 2019. INTERVENTION: Intervention pharmacies implemented workflows to co-dispense naloxone while usual care pharmacies provided usual services. MAIN MEASURES: Survey instruments assessed opioid risk behavior; hazardous drinking; tobacco, cannabis, and other drug use; and knowledge. Naloxone dispensings and opioid dose were evaluated using pharmacy data among pharmacy patients and survey participants. Intention-to-treat analyses were conducted using generalized linear mixed models accounting for clustering at the pharmacy level. KEY RESULTS: Opioid risk behavior did not differ by trial group (P=0.52; 8-month vs. baseline adjusted risk ratio [ARR] 1.07; 95% CI 0.78, 1.47). Compared with usual care pharmacies, naloxone dispensings were higher in intervention pharmacies (ARR 3.38; 95% CI 2.21, 5.15) and participant knowledge increased (P=0.02; 8-month vs. baseline adjusted mean difference 1.05; 95% CI 0.06, 2.04). There was no difference in other substance use by the trial group. CONCLUSION: Co-dispensing naloxone with opioids effectively increased naloxone receipt and knowledge but did not increase self-reported risk behavior. TRIAL REGISTRATION: Registered at ClinicalTrials.gov ; Identifier: NCT03337100.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Rachel Humeniuk; Robert Ali; Thomas F Babor; Michael Farrell; Maria L Formigoni; Jaroon Jittiwutikarn; Roseli B de Lacerda; Walter Ling; John Marsden; Maristela Monteiro; Sekai Nhiwatiwa; Hemraj Pal; Vladimir Poznyak; Sara Simon Journal: Addiction Date: 2008-03-28 Impact factor: 6.526
Authors: Reena K Sandhu; Michael V Heller; Jack Buckanavage; Benjamin Haslund-Gourley; Joshua Leckron; Brady Kupersmith; Nathaniel C Goss; Kyle Samson; Annette B Gadegbeku Journal: Harm Reduct J Date: 2022-07-02